Chitose and Fujifilm Biosciences sign biopharma manufacturing alliance

Chitose Laboratory and Fujifilm Biosciences have formed a strategic biopharma production alliance to combine the former’s cell line development skills with the latter’s culture media development and manufacturing capabilities.

The deal aims to accelerate biopharmaceutical manufacturing processes by generating highly productive cells that result in biopharmaceutical products with higher titers and greater quality.

To that end, the partners will use Japan-based Chitose’s proprietary CHO-MK cell line, optimising it with GMP manufactured cell culture platform media from the US headquartered Fujifilm Biosciences.

Takayuki Horiuchi, Chief Technology Officer at Chitose, said: “Together, the combined expertise of Chitose and Fujifilm Biosciences is set to create comprehensive solutions that not only enhance manufacturing efficiencies but also provide an integrated approach to tackling challenges in the global biopharma landscape.”

Yutaka Yamaguchi, Chairman and Chief Executive Officer at Fujifilm Biosciences, added: “This strategic alliance … underscores a shared vision of advancing therapeutic development by providing solutions designed to meet the growing demand for making biopharmaceuticals more accessible for treating conditions.

“Fujifilm Biosciences forms alliances with like-minded companies like Chitose to drive meaningful progress and to create a lasting impact across life sciences.”